In a patient with known heart failure with reduced ejection fraction who is currently pregnant, which heart failure medications should be stopped and which should be continued?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Heart Failure Medications in Pregnancy: Stop and Continue

In pregnant patients with HFrEF, immediately discontinue ACE inhibitors, ARBs, ARNIs, mineralocorticoid receptor antagonists (spironolactone), ivabradine, and SGLT2 inhibitors, while continuing beta-blockers (metoprolol, carvedilol, bisoprolol) and diuretics, and adding hydralazine and nitrates for afterload reduction. 1, 2

Medications to STOP Immediately

High-Risk Teratogenic Agents (Category D)

  • ACE inhibitors: Cause renal/tubular dysplasia, oligohydramnios, growth retardation, skull ossification disorders, lung hypoplasia, and intrauterine fetal death 3
  • ARBs (e.g., valsartan): Same fetal complications as ACE inhibitors - renal dysplasia, oligohydramnios, skeletal abnormalities 3
  • ARNIs: Contraindicated due to ACE inhibitor component 1, 2
  • Mineralocorticoid receptor antagonists (spironolactone): Must be discontinued 1, 2
  • Ivabradine: Contraindicated 1
  • SGLT2 inhibitors: Contraindicated 1

The 2021 Canadian guidelines and 2025 SMFM recommendations are unequivocal on this point - these medications should be stopped as soon as pregnancy is confirmed 1, 2.

Medications to CONTINUE

Beta-Blockers (Safe and Essential)

Continue metoprolol, carvedilol, or bisoprolol throughout pregnancy 1, 2. These are the cornerstone of HFrEF management during pregnancy and should not be interrupted. The 2025 SMFM guidelines specifically recommend against stopping beta-blockers in pregnant HFrEF patients 2.

Critical caveat: Do NOT use beta-blockers during acute decompensated heart failure - they should be held temporarily until hemodynamic stability is achieved 2.

Diuretics

Continue furosemide and other loop diuretics as needed for volume management 1, 2. These are safe and necessary for managing congestion during pregnancy.

Medications to ADD as Alternatives

For Afterload Reduction

  • Hydralazine: Safe alternative to ACE inhibitors/ARBs for afterload reduction 1, 2
  • Isosorbide dinitrate (nitrates): Can be combined with hydralazine for enhanced afterload reduction 1, 2

These medications replace the RAAS inhibition that must be discontinued and are the primary afterload-reducing agents safe for use during pregnancy.

Digoxin

Digoxin is the safest antiarrhythmic during pregnancy with extensive experience and can be used for rate control or inotropic support if needed 3.

Clinical Algorithm for Medication Management

  1. At pregnancy confirmation:

    • Stop: ACE-I/ARB/ARNI, spironolactone, ivabradine, SGLT2i immediately
    • Continue: Beta-blockers, diuretics
    • Start: Hydralazine ± nitrates for afterload reduction
  2. Reassess LV function without the contraindicated medications to improve risk stratification 1

  3. Monitor closely with serial echocardiography and BNP throughout pregnancy 1

  4. For acute decompensation during pregnancy:

    • Hydralazine or isosorbide dinitrate for afterload reduction
    • Furosemide for diuresis
    • Hold beta-blockers temporarily 2
  5. Postpartum management:

    • Restart ACE-I/ARB/ARNI immediately after delivery (unless breastfeeding - see below)
    • Continue beta-blockers
    • Resume full guideline-directed medical therapy 2

Breastfeeding Considerations

Most HF medications are compatible with breastfeeding, but review each medication individually 2. The 2011 ESC guidelines note that warfarin, digoxin, and verapamil are compatible with breastfeeding 3. However, the decision should involve shared decision-making given limited robust data 2.

Critical Pitfalls to Avoid

  • Do not delay discontinuation of ACE-I/ARB/ARNI once pregnancy is confirmed - fetal exposure in second and third trimesters causes the most severe complications 3
  • Do not stop beta-blockers thinking all HF medications are contraindicated - this increases maternal mortality risk 1, 2
  • Do not use atenolol - while some classify it as Category C, it has concerning data regarding fetal growth restriction; prefer metoprolol, carvedilol, or bisoprolol 3
  • Do not forget thromboprophylaxis - pregnant patients with HFrEF and EF <35% require pharmacologic thromboprophylaxis during pregnancy and for 6 weeks postpartum 2

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.